妊娠中后期应用抗乙型肝炎病毒药物治疗研究进展

Progress on treatment of anti-hepatitis B virus drug in middle and later period of pregnancy

《慢性乙型肝炎防治指南(2015年版)》提到若妊娠中后期患者乙型肝炎病毒载量>2×10~6 IU/ml,可于妊娠24~28周开始给予替诺福韦酯、替比夫定或拉米夫定治疗,以提高乙型肝炎病毒母婴阻断的成功率。本文将对慢性乙型肝炎病毒携带孕妇妊娠中后期抗病毒治疗的必要性、有效性及安全性,分娩后停用抗病毒药物出现ALT升高的预测因素分析,分娩后停用抗病毒药时机以及探索进一步提高母婴阻断成功率方法等进行综述。

＆quot;Chronic hepatitis B prevention and treatment guidelines （2015 edition）＆quot; pointed out that if hepatitis B virus load 〉 2 ＆#215; 106 IU/ml in late pregnancy, tenofovir, telbivudine or lamivudinecan should be administered at 24-28 weeks of pregnancy in order to improve the success rate of the prevention of mother-to-child transmission （PMTCT）. This paper reviews the necessity, effectiveness and safety of antiviral treatment in late pregnancy, predictors of ALT elevations, timing of deactivate antiviral drugs and ways to furtherly improve the success rate of PMTCT.